SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense & National Security, Space Solutions, and Starlab Space Stations. The Defense & National Security segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Space Solutions segment consists of space infrastructure, advanced space technology, science systems and mission services. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyager Technologies is trending as investors weigh strong backlog growth and a series of NASA and defense contracts against sector-wide volatility. The community is actively debating the company's long-term potential as a critical space infrastructure provider, closely watching for upcoming developments related to Starlab and potential breakthroughs in the space and defense budgets.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is attracting significant community attention as investors view it as a deeply undervalued AI-focused infrastructure play within the Base ecosystem. While some traders express frustration with short-term price volatility and manipulation, the active community is heavily focused on accumulating the token, citing its utility in autonomous AI agents and potential for long-term growth as a major market disruptor.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is seeing intense debate as investors weigh the potential for increased institutional adoption following the Senate Banking Committee's advancement of the CLARITY Act. While some community members anticipate a breakout driven by regulatory certainty and cross-border payment utility, others remain skeptical, citing long-term price stagnation and ongoing market manipulation concerns.

Gitlawb is a decentralized code collaboration platform designed for AI agents and human developers. It provides a Git-compatible hosting layer where repositories are stored across IPFS, Filecoin, and Arweave, and peer connectivity is handled through libp2p rather than a central server.  Identity on Gitlawb is based on decentralized identifiers (DIDs) using Ed25519 keys. Access control and delegation between users and agents are expressed as UCAN (User Controlled Authorization Networks) capabilities, allowing scoped, revocable permissions to be granted without a central authority. Each identity carries an on-chain trust score derived from verified contributions.  The protocol is accessed through three main surfaces: a Rust node (gitlawb-node) that serves repositories over HTTP and libp2p, a command-line client (gl) that handles identity, repositories, issues, bounties, and UCAN delegation, and a git remote helper (git-remote-gitlawb) that allows standard Git clients to push and pull using gitlawb:// URLs.  Additional products in the ecosystem include MiroClaw, an on-chain prediction market; Gitlawb Spawn, an AI agent orchestration tool; OpenClaude, an open-source agent harness aligned with Playground and Spawn; and a developer playground for testing agent interactions against the protocol.

Gitlawb

Gitlawb is gaining significant traction as community members highlight a robust token burn strategy, potential exchange listings, and strategic project collaborations. Investors are closely monitoring accumulation patterns and the development of its utility-driven infrastructure as key catalysts for continued momentum.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is trending as investors react to explosive revenue growth and expanding semiconductor testing capacity driven by high demand for AI and automotive chip components. Community members are actively debating the stock's valuation gap compared to other AI semiconductor plays, with many bulls focused on its recent capacity expansion in Malaysia as a catalyst for long-term growth.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing intense volatility as investors debate the significance of Berkshire Hathaway completely exiting its position, with some viewing it as a major signal while others dismiss it as a non-fundamental portfolio shuffle following leadership changes at the firm. The community remains deeply divided, with many bulls treating the dip as an attractive buying opportunity and dismissing the exit as a sign of poor decision-making by Berkshire's new management team.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. is attracting significant retail attention following a recent business combination and Nasdaq listing, with community discussion centered on its extremely low float and potential for rapid volatility. Investors are actively debating the company's prospects as a vertically integrated domestic alternative to foreign-dependent rare earth mineral supply chains.

eCash (XEC) is a Layer-1 digital cash network, developed by Bitcoin ABC. It was created on Nov 15th, 2020, and has since distinguished itself from its predecessors and other Bitcoin clients by integrating the breakthrough Avalanche consensus with its core proof-of-work (PoW) layer, extending its security and fundamental capabilities.  This Nakamoto/Avalanche hybrid consensus integration gives it unique properties for a Bitcoin-like chain, such as instant transaction finality, staking rewards, extensibility through subnets, and flexible protocol governance.  The development roadmap is set with three main goals: Scaling transaction throughput from ~100 tps to more than 5.000.000 tps Improving the payment experience with a less than 3 second transaction finality time Extending the protocol and establishing fork-free upgrades, allowing for more rapid, iterative development

eCash

eCash (XEC) is seeing heightened community attention following the successful activation of the Avalanche Pre-Consensus mainnet upgrade, which provides near-instant transaction finality. The community is actively discussing the network's enhanced technical capabilities, including the new heartbeat mechanism and recent developer tool improvements, as the project shifts focus toward real-world payment utility.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors debate the impact of a second FDA rejection for its melanoma treatment and the potential for a regulatory pivot following leadership changes at the agency. While some community members are betting on a reversal driven by political pressure and "right-to-try" initiatives, others are warning of significant dilution risks and a lack of a clear path forward for the company.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending as investors focus on the potential for clinical trial protocol changes to accelerate data maturation and expand the patient population, fueling speculation about a significant re-rating. The community is actively discussing the stock's high short interest and tight float, with many looking toward the upcoming AACR conference for potential trial updates that could trigger a major move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Protagenic Therapeutics, Inc. (PTIX) jumped 244% on Monday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=6&amp;b=2612&amp;ID=145678&amp;m=rl&amp;g=1834">announced</a> its merger with private pharmaceutical firm Phytanix Bio Inc.Protagenic said the two companies have entered into a definitive share exchange agreement, under which they will combine in an all-stock transaction.The combined entity will be called Phytanix, Inc., and will bring together the two companies’ pipelines focused on stress-related and central nervous system (CNS) disorders. While Protagenic makes peptides for stress-related disorders, Phytanix Bio specializes in developing medicines manufactured from cannabinoids and "cannabinoid-like" molecules.The combined entity will have five preclinical assets and one clinical-stage asset, Protagenic added.Protagenic executive chairman Garo H. Armen noted that the combination aligns two pipelines with complementary assets and expertise to develop drugs in neuropsychiatry, CNS, and other disorders.Protagenic said that post-combination, pre-financing ownership will be approximately 35% for the company's pre-combination stockholders and approximately 65% for Phytanix Bio stockholders on a fully diluted basis.Protagenic had announced a 1-for-14 reverse stock split of its issued and outstanding common stock earlier this month to bring the company into compliance with the minimum bid price requirement for continued listing on Nasdaq.On Stocktwits, retail sentiment around Protagenic jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_19_at_10_28_13_AM_png_a07fae3fc6.webp" alt="PTIX's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 19, 2025 | Source: Stocktwits" width="628" height="65"><figcaption>PTIX's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user believes the stock could rally further toward $15.<stembedurl>https://stocktwits.com/cjstocksup/message/615100995</stembedurl><a href="https://stocktwits.com/symbol/PTIX">PTIX stock</a> gained over 43% this year but is down by about 48% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/netflix-stock-edges-lower-after-jp-morgan-downgrade-despite-higher-price-target/ch0cubqRb82">Netflix Stock Edges Lower After JPMorgan Downgrade Despite Higher Price Target</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish

The new entity will be called Phytanix, Inc., and it will combine the two companies’ pipelines focused on stress-related and CNS disorders.

Equity

Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Current Price	$0.6499
Prev Close	$0.6499
Open	$0.6496
Dividend Yield	N/A
50-Day Moving Average	$0.6307
Beta	-0.34
Avg. Volume	8,508.95
PE Ratio	-0.16

52-Week High	$1.20
52-Week Low	$0.25
Market Capitalization	$1.18M
EPS (Annual)	N/A
Price to Book	-0.53
Revenue Per Employee	N/A

PTIX
Protagenic Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PTIX News

PTIXProtagenic Therapeutics Inc